This announcement is a separate document:
JCRファーマ：JCRファーマシューティカルズは、TEMCELL HS Injの製造中止を発表しました。新生児低酸素性虚血性脳症の適応症開発の拡大
JCR Pharmaceuticals: JCR Pharmaceuticals has announced the discontinuation of TEMCELL HS Inj manufacture, expanding the indications for developing neonatal hypoxic-ischemic encephalopathy.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.